Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Risk genes beyond APOE

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introducción: La enfermedad de Alzheimer se considera una de las patologías neurodegenerativas de mayor impacto en la salud pública, con una prevalencia y tasa de mortalidad en incremento. En su forma de inicio temprano, se ha vinculado estrechamente con mutaciones genéticas que alteran el procesamiento de la APP y por ende acumulación de placas Aβ, siendo los genes PSEN1 y PSEN2 los más implicados. Objetivo: Analizar la evidencia disponible sobre mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la enfermedad de Alzheimer. Metodología: Se realizó una revisión sistemática de la literatura, incluyendo estudios publicados entre 2019 y 2024, identificados a través de las bases de datos Scopus, PubMed y Taylor & Francis. La selección de estudios siguió los lineamientos PRISMA, y la calidad metodológica fue evaluada mediante la escala Newcastle-Ottawa (NOS). Resultados: Los estudios incluidos reportaron mutaciones frecuentes en PSEN1 (E280A, M146I, T274K) y en menor medida en PSEN2 (M239T), asociadas con una mayor proporción Aβ42/Aβ40 y un incremento en la acumulación de placas amiloides en tejido cerebral. Conclusiones: Las mutaciones en PSEN1 y PSEN2 se pueden considerar potenciales marcadores moleculares útiles para el diagnóstico temprano y la estratificación del riesgo en pacientes con sospecha de Alzheimer de origen genético.

What this study adds

Evidence grade: Low

This systematic review reports that mutations in PSEN1 and PSEN2 are linked to a higher Aβ42/Aβ40 ratio and more amyloid plaque buildup in brain tissue. The authors conclude these mutations may serve as molecular markers for early diagnosis and risk stratification in people with suspected genetic Alzheimer's, though the review itself does not test any treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tapia, M. J., & Prieto, C. (2025). Mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la Enfermedad de Alzheimer. Revisión Sistemática. MQRInvestigar. https://doi.org/10.56048/mqr20225.9.3.2025.e946

Vancouver

Tapia MJ, Prieto C. Mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la Enfermedad de Alzheimer. Revisión Sistemática. MQRInvestigar. 2025. doi:10.56048/mqr20225.9.3.2025.e946.

BibTeX

@article{tapia2025-741ba39d,
  author  = {Tapia, María José and Prieto, Carem},
  title   = {{Mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la Enfermedad de Alzheimer. Revisión Sistemática}},
  journal = {MQRInvestigar},
  year    = {2025},
  doi     = {10.56048/mqr20225.9.3.2025.e946},
  url     = {https://doi.org/10.56048/mqr20225.9.3.2025.e946}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This systematic review reports that mutations in PSEN1 and PSEN2 are linked to a higher Aβ42/Aβ40 ratio and more amyloid plaque buildup in brain tissue. The authors conclude these mutations may serve as molecular markers for early diagnosis and risk stratification in people with suspected genetic Alzheimer's, though the review itself does not test any treatment.

Study details

How this study scored 28/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 28 of 100.28 of 100 points earned72 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (MQRInvestigar)
Journal's citation record 0 / 4 MQRInvestigar: journal h-index 10 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Carem Prieto: h-index 7 (OpenAlex, whole career)
Institution's track record 0 / 3 Universidad Católica de Cuenca: institution h-index 55 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 28 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk genes beyond APOE from nearby years

Also in Risk genes beyond APOE

104 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →